红花黄色素联合依达拉奉治疗急性脑梗死的临床研究  

Clinical Study of Safflower Yellow Combined with Edaravone as Treatment of Acute Cerebral Infarction

作　　者：张勇[1] 胡勇[1] 穆振斌[1] 侯静[1] 侯玉梅[1] 王佐佑[1] 

机构地区：[1]解放军第313医院神经内科,辽宁葫芦岛125000

出　　处：《医学综述》2012年第15期2514-2515,共2页Medical Recapitulate

摘　　要：目的观察红花黄色素联合依达拉奉治疗急性脑梗死临床疗效。方法将65例急性脑梗死患者随机分为治疗组35例和对照组30例,对照组常规活血,抗血小板聚集药物同时予用红花黄色素治疗;治疗组在对照组基础上加用依达拉奉治疗。两组治疗前后采用美国国立卫生研究院卒中量表(NIHSS)和日常生活能力量表(BI)评分对患者的疗效进行评价。结果治疗后14 d两组NIHSS和BI评分均得到明显改善,差异有统计学意义(P<0.05);治疗组总有效率为80%,对照组总有效率为66.7%,两组比较差异有统计学意义(P<0.05)。结论红花黄色素联合依达拉奉治疗急性脑梗死安全有效,可改善患者的预后。Objective To assess the effects of safflower yellow combined with edaravone in acute cere- bral infarction. Methods 65 patients with acute cerebral infarction were randomly divided into the treatment group（ n = 35 ） which received treatment of safflower yellow with edaravone, and control group（ n = 30 ） which received treatment of safflower yellow. Both groups were given conventional blood circulation, anti-platelet ag- gregation drugs. Neural function of the two groups was assessed by NIHSS and BI before and after treatment. Results The difference of NIHSS score and BI between the treatment group and control group were signifi- cant after 14 days treatment（P 〈0.05 ）. It was found that total efficacy of treatment group was 80% which was higher than that of the control group（66.7% ）. There was a significant difference between the two groups （ P 〈 0.05 ）. Conclusion Safflower yellow combined with edaravone is safe and effective in the treatment of acute cerebral infarction, which may improve the prognosis.

关 键 词：红花黄色素 依达拉奉 急性脑梗死 

分 类 号：R743[医药卫生—神经病学与精神病学]